Read twice and referred to the Committee on the Judiciary.
This bill adds xylazine (including salts and isomers) to Schedule III of the Controlled Substances Act, defines and narrows the "ultimate user" exception mainly to veterinary and authorized animal-use contexts, and delays certain Schedule III compliance deadlines for labeling and practitioner registration. It requires ARCOS tracking updates, directs the Sentencing Commission to review penalties for offenses involving xylazine, and mandates two reports to Congress on illicit xylazine prevalence and origins.
Progressives stress public-health and fears criminalization of users
Narrow, technical scheduling change with carve-outs likely attracts bipartisan support but may face scrutiny on enforcement and veterinary impacts.
This bill adds xylazine (including salts and isomers) to Schedule III of the Controlled Substances Act, defines and narrows the "ultimate user" exception mainly to veterinary and authorized animal-use contexts, and delays certain Schedule III compliance deadlines for labeling and practitioner registration.
It requires ARCOS tracking updates, directs the Sentencing Commission to review penalties for offenses involving xylazine, and mandates two reports to Congress on illicit xylazine prevalence and origins.
The bill also exempts current manufacturers from immediate capital-security upgrades and instructs FDA and DEA to expedite necessary regulatory submissions.
A targeted scheduling bill with practical exemptions and reporting requirements fits common bipartisan patterns, but potential pushback on penalties and regulatory burdens limits certainty.
How solid the drafting looks.
Progressives stress public-health and fears criminalization of users
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives stress public-health and fears criminalization of users
Likely supportive of actions limiting illicit xylazine supply and improving data, but concerned about criminalization of people who use drugs.
Prefers stronger public-health, harm-reduction, and treatment components alongside enforcement measures.
Views the bill as a pragmatic, incremental step to restrict diversion and improve data on a rising danger.
Sees transitional provisions as sensible, but wants clarity on costs, enforcement consequences, and measurable public-health outcomes.
Likely supportive as a law-and-order response that gives prosecutors and regulators tools to curb illicit xylazine.
Appreciates protections for legitimate veterinary use but may want stronger enforcement or penalties.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
A targeted scheduling bill with practical exemptions and reporting requirements fits common bipartisan patterns, but potential pushback on penalties and regulatory burdens limits certainty.
The bill has not accumulated any surfaced votes yet.
Progressives stress public-health and fears criminalization of users
A targeted scheduling bill with practical exemptions and reporting requirements fits common bipartisan patterns, but potential pushback on…
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for Combating Illicit Xylazine Act.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.